drugset / Trial / NCT01679613

Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers

NCT01679613

Phase 1 Completed 34 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the current study is to investigate the relative bioavailability of a single dose of nintedanib low or high dose with and without coadministration of ketoconazole at steady state

Timeline

Start
2012-09
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule 400 mg Oral
Subject Nintedanib Small molecule 50 mg Oral

Indications

No indication recorded.